@phdthesis{Bender2009,
  author    = {Bender, Markus},
  title     = {Studies on platelet cytoskeletal dynamics and receptor regulation in genetically modified mice},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-48390},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2009},
  abstract  = {Blutpl{\"a}ttchen werden von Megakaryozyten im Knochenmark in einem Prozess produziert, an dem Aktin beteiligt ist. Aktin-Depolymerisierungsfaktor (ADF) und Cofilin sind Aktin-bindende Proteine, die als entscheidende Regulatoren im Aktinumsatz agieren, indem sie das Schneiden und Depolymerisieren von Filamenten unterst{\"u}tzen. Die Bedeutung von ADF/Cofilin und des Aktinumsatzes in der Bildung von Blutpl{\"a}ttchen ist gegenw{\"a}rtig nicht bekannt. In der vorliegenden Arbeit wurden M{\"a}use untersucht, die eine konstitutive ADF-Defizienz und/oder die eine konditionale n-Cofilin Defizienz (Cre/loxP) aufweisen. Um Cofilin nur in Megakaryozyten und Blutpl{\"a}ttchen auszuschalten, wurden Cofilinfl/fl M{\"a}use mit PF4-Cre M{\"a}usen verpaart. ADF- oder n-Cofilin-defiziente M{\"a}use hatten keinen oder nur einen geringen Ph{\"a}notyp in Blutpl{\"a}ttchen. Eine Defizienz von ADF und n-Cofilin f{\"u}hrte hingegen zu einem beinahe kompletten Verlust der Blutpl{\"a}ttchen, was mit Defekten in der Bildung von Pl{\"a}ttchenzonen in Knochenmark-Megakaryozyten einherging. Weitere Untersuchungen an in vitro und ex vivo kultivierten Megakaryozyten zeigten eine Reduzierung der Bildung von Propl{\"a}ttchen und das Fehlen der typischen Verdickungen der Propl{\"a}ttchen. Diese Daten zeigen redundante aber essentielle Funktionen von ADF und n-Cofilin im terminalen Schritt der Pl{\"a}ttchenbildung in vitro und in vivo, und belegen erstmals eine wichtige Rolle des Aktinumsatzes in diesem Prozess. Im zweiten Teil dieser Dissertation wurden die Mechanismen untersucht, die f{\"u}r die zellul{\"a}re Regulierung des Hauptkollagenrezeptors auf Blutpl{\"a}ttchen, Glykoprotein VI (GPVI), verantwortlich sind. Nach einer Gef{\"a}ßwandverletzung wird subendotheliales Kollagen freigelegt, wodurch GPVI die Aktivierung von Blutpl{\"a}ttchen vermittelt, und damit zur Blutstillung (H{\"a}mostase), aber auch zum Verschluss eines verletzten Gef{\"a}ßes beitragen kann, was letztendlich zu einem Myokardinfarkt oder einem Schlaganfall f{\"u}hren kann. Deshalb ist GPVI ein attraktives Zielprotein f{\"u}r eine anti-thrombotische Therapie, insbesondere weil fr{\"u}here Studien gezeigt haben, dass anti-GPVI Antik{\"o}rper eine irreversible Herunterregulierung des Rezeptors auf zirkulierenden Blutpl{\"a}ttchen mittels Internalisierung und Abspaltung induzieren. Es wird vermutet, dass Metalloproteinasen der ADAM (a disintegrin and metalloproteinase domain) - Familie das Abspalten vermitteln, jedoch fehlt in vivo der Beweis daf{\"u}r. Um die Mechanismen des Abspaltungsprozesses des GPVI Rezeptors in vivo besser verstehen zu k{\"o}nnen, wurden zwei Mauslinien, GPVI- und konditionale ADAM10-defiziente M{\"a}use, generiert und zus{\"a}tzlich sogenannte „low TACE (TNFalpha converting enzyme)" M{\"a}use analysiert. Es konnte gezeigt werden, dass GPVI in vitro von ADAM10 oder TACE in Abh{\"a}ngigkeit der Signalwege, die zum Abspalten des Rezeptors f{\"u}hren, geschnitten werden kann. Dar{\"u}berhinaus wurde GPVI in vivo nach Antik{\"o}rperverabreichung in ADAM10-defizienten M{\"a}usen und „low TACE" M{\"a}usen herunterreguliert, was vermuten l{\"a}sst, dass entweder beide Metalloproteinasen an diesem Prozess beteiligt sind oder noch eine zus{\"a}tzliche Metalloproteinase f{\"u}r die GPVI Regulation in vivo verantwortlich ist.},
  subject      = {Zellskelett},
  language  = {en}
}
@article{ChenRawatSamikannuetal.2021,
  author    = {Chen, Chunguang and Rawat, Divya and Samikannu, Balaji and Bender, Markus and Preissner, Klaus T. and Linn, Thomas},
  title     = {Platelet glycoprotein VI-dependent thrombus stabilization is essential for the intraportal engraftment of pancreatic islets},
  series = {American Journal of Transplantation},
  volume    = {21},
  journal   = {American Journal of Transplantation},
  doi       = {10.1111/ajt.16375},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-224471},
  pages     = {2079 -- 2089},
  year      = {2021},
  abstract  = {Platelet activation and thrombus formation have been implicated to be detrimental for intraportal pancreatic islet transplants. The platelet-specific collagen receptor glycoprotein VI (GPVI) plays a key role in thrombosis through cellular activation and the subsequent release of secondary mediators. In aggregometry and in a microfluidic dynamic assay system modeling flow in the portal vein, pancreatic islets promoted platelet aggregation and triggered thrombus formation, respectively. While platelet GPVI deficiency did not affect the initiation of these events, it was found to destabilize platelet aggregates and thrombi in this process. Interestingly, while no major difference was detected in early thrombus formation after intraportal islet transplantation, genetic GPVI deficiency or acute anti-GPVI treatment led to an inferior graft survival and function in both syngeneic mouse islet transplantation and xenogeneic human islet transplantation models. These results demonstrate that platelet GPVI signaling is indispensable in stable thrombus formation induced by pancreatic islets. GPVI deficiency resulted in thrombus destabilization and inferior islet engraftment indicating that thrombus formation is necessary for a successful intraportal islet transplantation in which platelets are active modulators.},
  language  = {en}
}
@article{CullmannJahnSpindleretal.2021,
  author    = {Cullmann, Katharina and Jahn, Magdalena and Spindler, Markus and Schenk, Franziska and Manukjan, Georgi and Mucci, Adele and Steinemann, Doris and Boller, Klaus and Schulze, Harald and Bender, Markus and Moritz, Thomas and Modlich, Ute},
  title     = {Forming megakaryocytes from murine-induced pluripotent stem cells by the inducible overexpression of supporting factors},
  series = {Research and Practice in Thrombosis and Haemostasis},
  volume    = {5},
  journal   = {Research and Practice in Thrombosis and Haemostasis},
  number    = {1},
  doi       = {10.1002/rth2.12453},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-224565},
  pages     = {111 -- 124},
  year      = {2021},
  abstract  = {Background Platelets are small anucleate cells that circulate in the blood in a resting state but can be activated by external cues. In case of need, platelets from blood donors can be transfused. As an alternative source, platelets can be produced from induced pluripotent stem cells (iPSCs); however, recovered numbers are low. Objectives To optimize megakaryocyte (MK) and platelet output from murine iPSCs, we investigated overexpression of the transcription factors GATA-binding factor 1 (GATA1); nuclear factor, erythroid 2; and pre-B-cell leukemia transcription factor 1 (Pbx1) and a hyperactive variant of the small guanosine triphosphatase RhoA (RhoAhc). Methods To avoid off-target effects, we generated iPSCs carrying the reverse tetracycline-responsive transactivator M2 (rtTA-M2) in the Rosa26 locus and expressed the factors from Tet-inducible gammaretroviral vectors. Differentiation of iPSCs was initiated by embryoid body (EB) formation. After EB dissociation, early hematopoietic progenitors were enriched and cocultivated on OP9 feeder cells with thrombopoietin and stem cell factor to induce megakaryocyte (MK) differentiation. Results Overexpression of GATA1 and Pbx1 increased MK output 2- to 2.5-fold and allowed prolonged collection of MK. Cytologic and ultrastructural analyses identified typical MK with enlarged cells, multilobulated nuclei, granule structures, and an internal membrane system. However, GATA1 and Pbx1 expression did not improve MK maturation or platelet release, although in vitro-generated platelets were functional in spreading on fibrinogen or collagen-related peptide. Conclusion We demonstrate that the use of rtTA-M2 transgenic iPSCs transduced with Tet-inducible retroviral vectors allowed for gene expression at later time points during differentiation. With this strategy we could identify factors that increased in vitro MK production.},
  language  = {en}
}
@article{RosaButtHopperetal.2022,
  author    = {Rosa, Annabelle and Butt, Elke and Hopper, Christopher P. and Loroch, Stefan and Bender, Markus and Schulze, Harald and Sickmann, Albert and Vorlova, Sandra and Seizer, Peter and Heinzmann, David and Zernecke, Alma},
  title     = {Cyclophilin a is not acetylated at lysine-82 and lysine-125 in resting and stimulated platelets},
  series = {International Journal of Molecular Sciences},
  volume    = {23},
  journal   = {International Journal of Molecular Sciences},
  number    = {3},
  issn      = {1422-0067},
  doi       = {10.3390/ijms23031469},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-284011},
  year      = {2022},
  abstract  = {Cyclophilin A (CyPA) is widely expressed by all prokaryotic and eukaryotic cells. Upon activation, CyPA can be released into the extracellular space to engage in a variety of functions, such as interaction with the CD147 receptor, that contribute to the pathogenesis of cardiovascular diseases. CyPA was recently found to undergo acetylation at K82 and K125, two lysine residues conserved in most species, and these modifications are required for secretion of CyPA in response to cell activation in vascular smooth muscle cells. Herein we addressed whether acetylation at these sites is also required for the release of CyPA from platelets based on the potential for local delivery of CyPA that may exacerbate cardiovascular disease events. Western blot analyses confirmed the presence of CyPA in human and mouse platelets. Thrombin stimulation resulted in CyPA release from platelets; however, no acetylation was observed—neither in cell lysates nor in supernatants of both untreated and activated platelets, nor after immunoprecipitation of CyPA from platelets. Shotgun proteomics detected two CyPA peptide precursors in the recombinant protein, acetylated at K28, but again, no acetylation was found in CyPA derived from resting or stimulated platelets. Our findings suggest that acetylation of CyPA is not a major protein modification in platelets and that CyPA acetylation is not required for its secretion from platelets.},
  language  = {en}
}